Cara Bess Janusz1, Abram L Wagner2, Nina B Masters2, Yaxing Ding3, Ying Zhang3, David W Hutton4, Matthew L Boulton5. 1. Department of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, USA. Electronic address: cjanusz@umich.edu. 2. Department of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, USA. 3. Division of Expanded Programs on Immunization, Tianjin Centers for Disease Control and Prevention, Tianjin 3000011, China. 4. Department of Health Management and Policy, University of Michigan, School of Public Health, Ann Arbor, USA. 5. Department of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, USA; Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, USA.
Abstract
BACKGROUND: Although global progress in measles control has been realized, achieving elimination has proven difficult in many regions of the world. China has adopted a goal of measles elimination but recent outbreaks predominantly affecting children <8 months who are ineligible for vaccination and incompletely protected by maternal antibodies has impeded progress. We assess the cost-effectiveness of adding an initial measles vaccine dose in China to earlier than the currently recommended 8 months of age. METHODS: We conducted a cost-utility analysis comparing the costs and health benefits associated with adding a measles vaccine dose to the routine schedule at 4, 5, 6 or 7 months compared to the current recommendation for the first dose at age 8 months. A decision analytic model was developed in Microsoft Excel, including five non-severe and two fatal health outcomes associated with measles infection. Model parameters were informed by the literature and surveillance data. Future costs and health benefits were discounted at 3%. Primary outcomes included costs, Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) over a lifetime time horizon. RESULTS: Lowering the recommended age for initiating the measles vaccination series to address susceptibility in children <8 months provided incremental health gains compared to minimal costs at the individual-level. The ICER was most favorable ($232.70 per QALY gain) for administering an initial dose at 4 months of age due to fewer incremental program costs when shifting measles administration to an immunization visit already established under the Chinese vaccination program. CONCLUSION: We found potential beneficial health gains at a minimum cost associated with adding an earlier measles dose <8 months of age in China. Further investigation about disease transmission dynamics is required to more fully assess the tradeoffs of administering measles at a younger age to infants in China.
BACKGROUND: Although global progress in measles control has been realized, achieving elimination has proven difficult in many regions of the world. China has adopted a goal of measles elimination but recent outbreaks predominantly affecting children <8 months who are ineligible for vaccination and incompletely protected by maternal antibodies has impeded progress. We assess the cost-effectiveness of adding an initial measles vaccine dose in China to earlier than the currently recommended 8 months of age. METHODS: We conducted a cost-utility analysis comparing the costs and health benefits associated with adding a measles vaccine dose to the routine schedule at 4, 5, 6 or 7 months compared to the current recommendation for the first dose at age 8 months. A decision analytic model was developed in Microsoft Excel, including five non-severe and two fatal health outcomes associated with measlesinfection. Model parameters were informed by the literature and surveillance data. Future costs and health benefits were discounted at 3%. Primary outcomes included costs, Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) over a lifetime time horizon. RESULTS: Lowering the recommended age for initiating the measles vaccination series to address susceptibility in children <8 months provided incremental health gains compared to minimal costs at the individual-level. The ICER was most favorable ($232.70 per QALY gain) for administering an initial dose at 4 months of age due to fewer incremental program costs when shifting measles administration to an immunization visit already established under the Chinese vaccination program. CONCLUSION: We found potential beneficial health gains at a minimum cost associated with adding an earlier measles dose <8 months of age in China. Further investigation about disease transmission dynamics is required to more fully assess the tradeoffs of administering measles at a younger age to infants in China.
Authors: Matthew L Boulton; Xiexiu Wang; Ying Zhang; JoLynn P Montgomery; Abram L Wagner; Bradley F Carlson; Yaxing Ding; Xiaoyan Li; Brenda Gillespie; Xu Su Journal: Vaccine Date: 2016-05-03 Impact factor: 3.641
Authors: Matthew L Boulton; Xiexiu Wang; Abram L Wagner; Ying Zhang; Bradley F Carlson; Brenda W Gillespie; Yaxing Ding Journal: J Infect Dis Date: 2017-11-27 Impact factor: 5.226
Authors: Christian Pou; Dieudonné Nkulikiyimfura; Ewa Henckel; Axel Olin; Tadepally Lakshmikanth; Jaromir Mikes; Jun Wang; Yang Chen; Anna Karin Bernhardsson; Anna Gustafsson; Kajsa Bohlin; Petter Brodin Journal: Nat Med Date: 2019-03-18 Impact factor: 53.440
Authors: Melanie Y Bertram; Jeremy A Lauer; Kees De Joncheere; Tessa Edejer; Raymond Hutubessy; Marie-Paule Kieny; Suzanne R Hill Journal: Bull World Health Organ Date: 2016-09-19 Impact factor: 9.408
Authors: Paul A Gastañaduy; Emily Banerjee; Chas DeBolt; Pamela Bravo-Alcántara; Samia A Samad; Desiree Pastor; Paul A Rota; Manisha Patel; Natasha S Crowcroft; David N Durrheim Journal: Hum Vaccin Immunother Date: 2018-07-11 Impact factor: 3.452